Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,023.80 -15.71 (-1.51%)

Official Closing Price Updated: 4:10 PM EST, Jan 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

The Silicon Laureates: How 2024’s ‘Nobel Prize Moment’ Rewrote the Laws of Scientific Discovery

January 14, 2026

The history of science is often measured in centuries, yet in October 2024, the timeline of human achievement underwent a tectonic shift that is only now being fully understood in early 2026. By...

Via TokenRing AI

Topics Artificial Intelligence Electric Vehicles

Behind the Scenes of Eli Lilly and Co's Latest Options Trends ↗

January 14, 2026

Via Benzinga

The Digital Microscope: How AlphaFold 3 is Decoding the Molecular Language of Life

January 14, 2026

As of January 2026, the landscape of biological research has been irrevocably altered by the maturation of AlphaFold 3, the latest generative AI milestone from Alphabet Inc. (NASDAQ: GOOGL). Developed...

Via TokenRing AI

Topics Artificial Intelligence Bonds

January 13, 2026

Via Stocktwits

Eli Lilly & Co (NYSE:LLY) Combines High Growth Momentum with a Strong Technical Setup ↗

January 13, 2026

Via Chartmill

Eli Lilly's Most Promising Weight Loss Drug May Come With a Surprising Benefit: Pain Relief ↗

January 14, 2026

Retatrutide is an exciting GLP-1 drug that has explosive potential.

Via The Motley Fool

Why Eli Lilly Stock Gained 39.2% In 2025 ↗

January 14, 2026

The company is benefiting mightily from its portfolio of weight-loss drugs.

Via The Motley Fool

Slimmer Waistlines, Fatter Margins: Jefferies Says Airline Companies Will Profit From America’s Weight-Loss Boom ↗

January 14, 2026

Via Stocktwits

Healthcare Sector Stages Resilient Rebound as Policy Clarity and GLP-1 Innovations Fuel Investor Optimism

January 14, 2026

The U.S. healthcare sector has entered 2026 on a remarkably strong footing, staging a decisive rebound after a tumultuous 2025. This resurgence is being driven by a rare alignment of legislative...

Via MarketMinute

Topics Earnings Economy

The Great Tariff-Inflation Tug-of-War: Why the Fed’s 2% Target Remains Elusive in 2026

January 14, 2026

As the United States enters the first quarter of 2026, the global economy is grappling with a radical shift in trade dynamics that has upended decades of globalization. The aggressive...

Via MarketMinute

Topics Economy Supply Chain World Trade

Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗

January 14, 2026

Plenty of growth lies ahead for these top healthcare companies.

Via The Motley Fool

A Fresh IPO That Long-Term Investors Shouldn’t Ignore ↗

January 14, 2026

Via MarketBeat

Topics Initial Public Offering

Is It Time to Dump Your Shares of Eli Lilly? ↗

January 14, 2026

What happens with Eli Lilly's GLP-1 shot now that Novo Nordisk has come out with a GLP-1 pill?

Via The Motley Fool

Topics Intellectual Property

Jim Cramer Calls Nvidia, Eli Lilly Partnership 'Monumental Effort' To 'Speed Up' Critical Drug Creation ↗

January 14, 2026

Jim Cramer calls Nvidia-Eli Lilly partnership a "monumental effort" to speed up drug creation, despite Wall Street ignoring major AI shift.

Via Benzinga

Topics Artificial Intelligence

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns ↗

January 13, 2026

Via MarketBeat

Why This Fund Made a $72 Million Bet on a Stock Headed for a $210 Per Share Takeout ↗

January 13, 2026

Chart Industries delivers engineered cryogenic and heat transfer equipment to energy and industrial gas markets worldwide.

Via The Motley Fool

Topics Supply Chain

The Great Recalibration: Why 2026 Could Be Healthcare’s Year to Rebound

January 13, 2026

For the past two years, the U.S. healthcare sector has been the forgotten stepchild of the equity markets. As the S&P 500 (SPX) surged on the back of an artificial intelligence gold rush and a...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Amgen at the Crossroads: MariTide, Market Volatility, and the Quest for Obesity Dominance

January 13, 2026

Date: January 13, 2026 Introduction Amgen Inc. (NASDAQ: AMGN) finds itself at a historic crossroads. Long regarded as the "blue-chip" anchor of the biotechnology sector, the Thousand Oaks-based giant...

Via PredictStreet

Topics Economy Intellectual Property

Nvidia, Eli Lilly Launch $1 Billion AI Lab To Build Meds ↗

January 13, 2026

NVIDIA and Eli Lilly launch a $1 billion AI lab to speed drug discovery, improve manufacturing, and apply artificial intelligence across research, clinical trials, and supply chains over the next five...

Via Benzinga

Topics Artificial Intelligence

Eli Lilly vs Novo Nordisk: Which Company Will Dominate the Weight Loss Drug Market in 2026? ↗

January 13, 2026

Both companies now aim to win in the oral weight loss drug market.

Via The Motley Fool

Cooling Inflation Ignites Market Optimism: December CPI Report Paves Way for Fed Pivot

January 13, 2026

The Bureau of Labor Statistics released the December 2025 Consumer Price Index (CPI) report on the morning of January 13, 2026, revealing a headline inflation rate of 2.7%. While the headline figure...

Via MarketMinute

Topics Artificial Intelligence Bonds Credit Cards

Can Novo Nordisk Unseat Eli Lilly as the Weight Loss Drug Leader in 2026? ↗

January 13, 2026

The gap may be too hard to close in the next 12 months.

Via The Motley Fool

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

January 13, 2026

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

Via Barchart.com

Is the Vanguard Dividend Appreciation ETF a Buy Now? ↗

January 13, 2026

This Vanguard ETF could be appealing to investors seeking both growth and income.

Via The Motley Fool

Topics ETFs Regulatory Compliance

Why Tempus AI Stock Rose Today ↗

January 12, 2026

The data provider's artificial intelligence-driven solutions are accelerating drug discovery.

Via The Motley Fool

Topics Artificial Intelligence

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

Via TokenRing AI

Topics Artificial Intelligence

Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security

January 12, 2026

On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the...

Via TokenRing AI

Topics Artificial Intelligence

This NVIDIA Partnership Shows How Big AI Can Really Get ↗

January 12, 2026

Via MarketBeat

Topics Artificial Intelligence

Nvidia Stock Continues To Crawl But Analysts See Strong Upside Ahead ↗

January 12, 2026

Nvidia said on Monday that it will partner with Eli Lilly to fund a new artificial intelligence research lab, committing up to $1 billion over five years.

Via Talk Markets

Topics Artificial Intelligence

Nvidia Partners With Biotech Firms On AI Drug Discovery ↗

January 12, 2026

Nvidia announced AI partnerships with biotech firms to transform the way lifesaving drugs are discovered and manufactured. Nvidia stock rose.

Via Investor's Business Daily

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.